Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00857025 · ClinicalTrials.gov registry record · Phase 1

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 1 study, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00857025 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00857025, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan in treating patients with locally advanced or metastatic non-small cell lung cancer.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER questionnaire administration
  • OTHER flow cytometry
  • BIOLOGICAL beta-glucan MM-10-001

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-11-21
Est. Completion 2021-05-18
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT00857025

The ClinicalTrials.gov registry entry for NCT00857025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00857025 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00857025 about?

NCT00857025 is a clinical study titled "Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan in treating patients with locally advanced or metastatic non-small cell lu...

What is the current status of trial NCT00857025?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-11-21. Estimated completion is 2021-05-18.

What interventions are being tested in trial NCT00857025?

The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), flow cytometry (OTHER), beta-glucan MM-10-001 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00857025?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.